Drotrecogin alfa (activated): real-life use and outcomes for the UK

INTRODUCTION: In March 2001, the results of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study were published, which indicated a 6.1% absolute reduction in 28-day mortality. Drotrecogin alfa (activated; DrotAA) was subsequently approved for use in patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Rowan, Kathryn M, Welch, Catherine A, North, Emma, Harrison, David A
Format: Artigo
Language:Inglês
Published: BioMed Central 2008
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2447613/
https://ncbi.nlm.nih.gov/pubmed/18430215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc6879
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items